Speaker Profile

M.D., Chief Medical Officer, Agilent Technologies

Dr. Kate Knobil joined Agilent in April 2021 as the company’s first Chief Medical Officer and is helping to expand Agilent’s leadership in precision medicine and the development of novel therapeutics to improve patient outcomes. Kate has more than 20 years of experience in clinical development and medical affairs while serving in global strategic leadership roles. Prior to joining Agilent, Kate was CMO and head of R&D at Kaleido Biosciences, applying her pharmaceutical experience to help translate the promise of the microbiome into solutions for patients. Prior to Kaleido, Kate served in a variety of leadership roles at GlaxoSmithKline, including head of late-stage clinical development in China, head of value evidence and outcomes, and CMO.

 Session Abstract – PMWC 2022 Silicon Valley

As targeted therapies have opened up precision medicine approaches to cancer treatment, oncologists and patients are increasingly moving to liquid biopsy as a front-line diagnostic approach to detection of actionable mutations to enable faster treatment decisions. Mutation detection in ctDNA has been shown to highly correlate to tissue biopsy for making treatment decisions, faster results and has the additional advantage of simplified specimen collection. Liquid biopsy represents an emerging paradigm shift in oncology practice and this session will discuss its promise and challenges from the Pharma, biotech and medical affairs perspectives.